Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

BACKGROUND: Human epidermal growth factor 2 (HER2/ERBB2) is frequently amplified/mutated in cancer. The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive breast cancer. Direct comparisons of the preclinical efficacy of the TKIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Conlon, Neil T., Kooijman, Jeffrey J., van Gerwen, Suzanne J. C., Mulder, Winfried R., Zaman, Guido J. R., Diala, Irmina, Eli, Lisa D., Lalani, Alshad S., Crown, John, Collins, Denis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007737/
https://www.ncbi.nlm.nih.gov/pubmed/33473169
http://dx.doi.org/10.1038/s41416-020-01257-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007737/
https://www.ncbi.nlm.nih.gov/pubmed/33473169
http://dx.doi.org/10.1038/s41416-020-01257-x

Ejemplares similares